In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a price target of $35.00. The company’s shares closed yesterday at $9.96.
Catanzaro covers the Healthcare sector, focusing on stocks such as Keros Therapeutics, Nurix Therapeutics, and Exelixis. According to TipRanks, Catanzaro has an average return of 6.0% and a 42.55% success rate on recommended stocks.
Currently, the analyst consensus on Nurix Therapeutics is a Strong Buy with an average price target of $26.25.
See the top stocks recommended by analysts >>
The company has a one-year high of $13.99 and a one-year low of $4.22. Currently, Nurix Therapeutics has an average volume of 793.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nurix Therapeutics (NRIX) Company Description:
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company’s pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Read More on NRIX:
- Nurix Therapeutics expects cash runway into 2H25
- Nurix Therapeutics provides 2024 goals, catalysts
- Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
- Nurix Therapeutics to hold a pharmaceutical update conference call
- Oppenheimer says too early to make call on Nurix Therapeutics’ NX-5948
